Floatz logo

Pen-866

Squamous Cell Carcinoma of the Anus

Tarveda TherapeuticsPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

28 Active assets in the Squamous Cell Carcinoma of the Anus cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Columbia University
Phase 2BB
Carboplatin
Fudan University
Phase 3BB
Nivolumab
National Cancer Institute (NCI)
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3BB
Atezolizumab
Oncolytics Biotech
Phase 2B

View all 39 →

Same molecule, other indications

Pen-866 is also rated in:

endometrium adenocarcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
pancreatic adenocarcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
cervical squamous cell carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →